Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 18/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.54 |
| ▸ | PRKDC | P78527 | 1/20 | 0.54 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1791905 | 0.87 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL1790874 | 0.84 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188542 | 0.83 | PIK3CG (0.63) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL12364310 | 0.82 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL16029783 | 0.82 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL3690862 | 0.81 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188717 | 0.81 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL4507516 | 0.81 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189118 | 0.80 | PIK3CG (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL190084 | 0.80 | PIK3CG (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | EXELIXIS, INC. (US) | 2011-08-25 | — | — | US | claimed |
| EP-2364974-A1 | N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors | Exelixis, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | PIK3CA, PIK3CB, PIK3CG | PIK3CG 3/4885PIK3CD 4/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.